KPV 5mg

Description

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH) that retains the parent molecule’s anti-inflammatory activity while offering reduced systemic receptor engagement and improved localized tissue selectivity.

Research Overview

α-MSH’s anti-inflammatory properties were first characterized through its actions at melanocortin receptors expressed on immune cells and epithelial surfaces. Subsequent work identified KPV as the minimal active sequence responsible for much of this activity, enabling study of targeted anti-inflammatory signaling without the full melanotropic profile of α-MSH. Research published in Inflammatory Bowel Diseases demonstrated significant reductions in inflammatory markers and mucosal injury scores in rodent colitis models following KPV treatment, establishing it as a focus in inflammatory bowel disease research. Mechanistic studies have characterized KPV’s ability to inhibit NF-κB pathway activation, reducing downstream production of IL-1β, IL-6, and TNF-α in both immune and epithelial cell systems. A mechanistically notable finding across several studies is KPV’s apparent capacity for direct cellular internalization in epithelial cells — allowing intracellular anti-inflammatory activity beyond surface receptor engagement. Skin wound healing models have shown accelerated epithelialization in inflammatory injury contexts. Research teams continuing work on melanocortin system fragments use KPV as a selective tool for characterizing MC1R-independent anti-inflammatory signaling and intestinal mucosal repair pathways.

Key References

• Kannengiesser K et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine experimental colitis. Inflammatory Bowel Diseases.
• Brzoska T et al. (2008). Alpha-MSH and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo. Endocrine Reviews.
• KPV anti-inflammatory mechanism in epithelial models. [PubMed Search]